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ABSTRACT 
 
Background: 
                      Salivary biomarkers are extensively studied in various fields of 
dentistry. Carboxyterminal telopeptide of type I collagen (CTX), a degradation 
product which is a marker of bone resorption is released into tissues during 
periodontal disease process and reaches the saliva via GCF. Changes in salivary CTX 
levels can be used to detect and monitor periodontal disease activity. 
Aim: 
                  The aim of the present study is to analyse the effect of phase I therapy in 
chronic periodontitis subjects by evaluating the salivary CTX levels and to compare 
and correlate the salivary CTX levels with clinical parameters. 
Materials and methods: 
                  Salivary CTX levels were determined in patients with chronic 
periodontitis, n=25 (study group) and healthy controls (n=20) using Enzyme linked 
Immunosorbent Assay (ELISA). The salivary CTX levels were compared and 
correlated with clinical parameters namely PI, GBI, PPD, CAL before and after phase 
I therapy.  
Results:  
                 There was statistically significant increase in salivary CTX levels in the 
study group when compared to the control group (p<0.01), and these levels reduced 
significantly after treatment. Positive correlation was shown between the clinical 
parameters and salivary CTX levels but the correlation was not significant in both the 
groups (p>0.05). 
Conclusion: 
                  In the present study, there was a significant difference in salivary CTX 
levels between the groups and a significant decrease in these levels was observed after 
phase I therapy in the study group. This signifies that the detection of CTX in saliva 
may be useful to detect individuals at risk, the periodontal disease activity and its 
response to periodontal therapy. 
Key words: Carboxyterminal telopeptide of type I collagen (CTX), bone 
resorption           markers, chronic periodontitis                                            
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INTRODUCTION 
                     The presence of active periodontal disease with continuing attachment 
loss threatens the oral health, comfort and function of the patient. If the disease 
activity could be determined, therapeutic measures may be fashioned for individual 
patients. Recently, the field of Periodontics has advanced dramatically in different 
ways to assess sites and individuals with active disease. 
                Proteolytic enzymes play a major role in the destruction of periodontium 
during the disease process. These enzymes (collagenases, proteases, aminopeptidases 
etc.) and their breakdown products are considered as markers of periodontal disease 
activity.
86
 
             During the initial phase bone resorption, the pH at the site is acidic. As a 
result, cathepsin K (cysteine protease) released from the osteoclasts attacks the type I 
collagen at multiple sites, including several sites in the helical region.
35
 Thus, the 
triple helix becomes more susceptible to further action of other enzymes like MMP’s 
at neutral pH.
2, 37, 85
 Two of the degradation product from the C – terminal telopeptide 
region of type I collagen are
37
: 
i. Carboxyterminal telopeptide of type I collagen (CTX)  
ii. Pyridinoline cross linked carboxyterminal telopeptide of type I 
collagen (ICTP / CTX – MMP)85 
                   Carboxyterminal telopeptide of type I collagen (CTX) is an octapeptide 
(Glu – Lys – Ala – His – Asp – Gly – Gly – Arg) found at the cross linking site of the 
alpha 1 (I chain) chain at the C – terminal telopeptide region of type I collagen.85 
_________________________________________________________________________Introduction 
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                  CTX is generated by cathepsin K, but ICTP is destroyed by this enzyme. 
ICTP is generated by the action of MMP’s such as MMP – 9 and MMP – 12. Thus 
ICTP is termed as CTX – MMP.37, 85 CTX is considered as the most specific and 
sensitive marker to monitor metabolic bone diseases and physiological bone 
turnover.
37
It can be detected from samples by Enzyme linked Immunosorbent Assay 
(ELISA) using highly specific monoclonal antibodies.
14, 80
 
Unstimulated, whole saliva represents a pooled sample of all periodontally 
diseased sites.
18
Hence, saliva was used to analyse the level of this biomarker in 
generalized chronic periodontitis patients. 
 The present study was conducted to determine the effect of Phase I 
therapy in generalized chronic periodontitis patients by evaluating salivary CTX levels 
before and after periodontal therapy. 
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                                                  AIM AND OBJECTIVES 
 AIM: 
      The aim of the study is to determine the effect of phase I therapy in 
generalized chronic periodontitis patients by evaluating the salivary levels of CTX 
using Enzyme Linked Immunosorbent Assay (ELISA). 
 
OBJECTIVES: 
1. To compare salivary CTX levels between generalized chronic periodontitis 
patients (study group) and healthy controls (control group). 
2. To compare salivary CTX levels before and after phase I therapy in study 
group. 
3. To correlate salivary CTX levels with clinical parameters like bleeding on 
probing, Plaque Index, Probing pocket depth and Clinical attachment level in 
both the groups. 
 
 4 
 
REVIEW OF LITERATURE 
             Bone is a dynamic connective tissue that undergoes continuous remodeling by 
two counteracting processes, namely bone formation and bone resorption. These 
processes rely on the activity of osteoclasts (resorption), osteoblasts (formation) and 
osteocytes (maintenance).
62
  
 
TYPE I COLLAGEN  
              Type I collagen comprises 90% of the organic matrix of bone and is the most 
abundant collagen in osseous tissues.
68
 Like other types of collagen, type I collagen 
also comprises three polypeptide chains (α-chains) which form a unique triple-helical 
structure. It is a heterotrimer of two α1(I) and one α2(I) chains. The α1 (I) chain is 
more conserved than the α2 (I) chain.52 The N (amino) and C (carboxy) terminal 
telopeptides, do not have a repeating Gly-X-Y structure and do not adopt a triple 
helical conformation. These account for 2% of the molecule and are essential for fibril 
formation. The telopeptides are the most immunogenic regions of type I molecule.
49,50
 
 
CROSS LINKS: 
               The strength of the collagen fibre depends on the formation of covalent 
cross-links between the telopeptide and adjacent helical domains of collagen 
molecules. Type I collagen has four cross-linking sites: one in each telopeptide and 
two others at the sites in the triple-helical domain at residues 87 and 930.
78
 
____________________________________________________________________Review of literature 
5 
 
 
 
 
 
Figure1.  AMINO- AND CARBOXY-TERMINAL TELOPEPTIDES OF TYPE    
I COLLAGEN (Calvo et al 1996) 
 
                      The enzyme needed for forming cross links is lysyl oxidase. The 
divalent cross links are formed between the collagen telopeptide region and the helical 
region. These crosslinks can be reduced, hence termed as reducible crosslinks.
87
 
                        The mature cross-linking residues are trivalent 3- hydroxypyridinium 
residues, lysyl pyridinoline (LP or Dpd or D-Pyr) and hydroxylysylpyridinoline (HP 
or Pyr). These trivalent cross-links connect together two telopeptide chains and one 
helical domain in a separate collagen molecule.
20
 
                  An inborn defect with inhibited collagen cross-linking leads to severe 
diseases, e.g. Ehlers-Danlos syndrome, Marfan syndrome, Menke's disease or X-
linked form of cutis laxa.
5
 
 
____________________________________________________________________Review of literature 
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RESORPTION OF BONE: 
                Resorption of bone is accomplished by the multinucleated osteoclast. This 
cell attaches to mineralized surfaces of the bone and forms a unique resorption area.  
The ruffled border of the osteoclast is sealed from the cell – surrounding environment 
by the clear zone. One of the first steps in the resorption sequence is acidification of 
the ruffled border area. The low pH results in dissolution of the mineral, thus exposing 
the collagenous and noncollagenous bone matrix.
5,30
 
             A subsequent enzymatic attack of the matrix constituents leads to the final 
degradation of the bone. Two types of proteinases may participate at this level: the 
cysteine proteinases namely Cathepsin K, which acts preferably at acidic pH, and the 
matrix metalloproteinases (MMP), which acts at neutral pH.
35, 63
  
Cathepsin K  
              Cathepsin K, a cysteine protease is the major collagen degrading enzyme 
which is secreted by the osteoclasts. It belongs to a papain superfamily of cysteine 
proteinases and is highly cell and tissue specific, concentrating in the osteoclasts of 
the resorbing bone.
22
 Cathepsin K is concentrated along the ruffled border of the 
osteoclasts facing the bone resorption lacunae, and also in vesicles, granules and 
vacuoles close to the resorption zone.
89
 The other bone cells, such as osteoblasts, 
osteocytes and bone marrow cells, elicit no cathepsin K expression.
61,89
 Cathepsins S, 
B and L are expressed at very low levels by the osteoclasts.
23
 
                      Though cathepsin K is a highly bone-specific enzyme, the different 
bones contain variable amounts of cathepsin K activity.  Long bones and vertebrae 
____________________________________________________________________Review of literature 
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where rapid bone remodeling occurs contain more cathepsin K than the bones with 
low resorption rate, such as calvariae.
31,38
 
                  Cathepsin K is autoactivated at acidic pH and in sites with elevated 
temperatur.
7,56
 The maximal enzyme activity at pH 5.5 (acidic).
7
 Cathepsin K has 
unique property to cleave collagen both outside the helical region
35
 and at multiple 
regions inside the helix.
9
 
Matrix metalloproteinases: 
                    MMPs are activated by tissue or plasma proteinases, opportunistic 
bacterial proteinases or by the uPA/plasmin system.
45,66
 Several MMPs participate in 
collagen degradation and have been identified during bone resorption using different 
assays. These include the collagenases (MMP–1, - 2, -13, and – 14) and the 
gelatinases (MMP – 2, MMP – 9).37 
                  The predominant MMPs in the pathogenesis of periodontitis are MMP 8 
(collagenase 2), MMP 9 (gelatinase B) and MMP 13 (collagenase 3).
43
 MMP 9 is 
highly expressed in the osteoclasts.  In vitro experiments have detected maximal 
activity of MMP 9 at pH of 7.5.
36
 MMP 8 and 13 are neutrophil and bone cell derived 
MMPs respectively. MMP 8 is a strong biomarker candidate for detecting alveolar 
bone destruction.
43
 
                    DEGRADATION PRODUCTS OF TYPE I COLLAGEN 
            Collagen degradation products include pyridinoline, deoxypyridinoline, 
amino-terminal peptides (N-terminal) and carboxy-terminal (C-terminal) telopeptides. 
The pyridinium cross-links, pyridinoline (Pyr) and deoxypyridinoline (Dpyr) are 
trifunctional cross-links that together with other di-, tri-, and tetrafunctional cross-
____________________________________________________________________Review of literature 
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links stabilize the collagen structure within the extracellular matrix. Pyr is found 
mainly in bone and cartilage. Dpyr is present mainly in bone and dentin.
33
  
      
 
 
Figure 2: An illustration of the breakdown products of type I collagen at 
N and C terminal end
62 
                
                       The critical cysteine proteinase cathepsin K, which is selectively 
expressed by osteoclasts, is extremely efficient in type I collagen degradation.
36,39 
Cathepsin K which is active at acidic pHdigests the organic matrix and releases 
carboxyterminal telopeptide of type I collagen degradation (CTX) – the eight amino 
acid sequence. As the pH increases, MMPs exert their activity and 10kDa peptide 
namely the cross -linked C- telopeptide of type I collagen (ICTP) is released. 
____________________________________________________________________Review of literature 
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                      Released ICTP can be further destroyed by cathepsin K
37
 which can 
activate an osteoclastic enzyme, tartrate – resistant acid phosphatase type 5b 
(TRACP5b).
91
  
                      TRACP 5b has been detected in ruffled border of an osteoclast 
membrane and has an inherent ability to further degrade partly degraded type I 
collagen products.
44 
 
Methods to evaluate the degradation products of type I collagen
62 
Hydroxypyridinium crosslinks  
Pyridinoline (PYD)                   -   HPLC, EIA  
Deoxypyridinoline (DPD)        -   HPLC, EIA 
 Crosslinked telopeptide: 
ICTP (CTX-MMP, carboxyterminal type I collagen telopeptide) - RIA 
CTX / βCTX (Linear octapeptide derived from carboxyterminal type I collagen 
telopeptide)   -   ELISA 
NTX (Aminoterminal crosslinked type I collagen telopeptide) - ELISA  
                        
      CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN (CTX) 
                          CTX is an octapeptide with an aminoacid sequence Glu-Lys-Ala-His-
Asp-Gly-Gly-Arg. It is cleaved by the action of Cathepsin K enzyme on the 
crosslinking site of the alpha 1 chain of the type I collagen in carboxy-terminal 
telopeptide region.
86
 
                       The CTX epitope contains an aspartyl-glycine motif (DG), which can 
undergo spontaneous isoaspartyl transformation. During the synthesis of new 
collagen, this motif in the native aspartyl form denoted as α CTX, gets spontaneously 
____________________________________________________________________Review of literature 
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converted to isoaspartyl form (denoted β CTX) during aging of the bone matrix. The 
isomerization reaction occurs spontaneously in bone under physiological conditions. 
Quantification of the relative amounts of the newly synthesized α CTX form 
compared with the age modified β CTX form (α/βratio) can detect the average age of 
the resorbed bone collagen.
15,16,20.21
 
                     
FORMATION OF CTX DURING BONE RESORPTION: 
                During bone resorption, owing to the low pH at the ruffled border area of 
the osteoclast, Cathepsin K is released from the osteoclast.  Cathepsin K has the 
ability to generate CTX from insoluble human collagen.
37
 The larger Cathepsin K 
generated fragments are not detected by the antibody designed to recognize an eight 
amino acid sequence from CTX, and that they become detectable on further 
fragmentation by MMPs. Once this C – terminal fragments are generated, pH 
increases and they become liable to the action of MMPs.
37
 
              Thus a contribution of MMPs to CTX immunoreactivity once initiated by 
cathepsin K is compatible with the model of osteoclast – mediated resorption 
proposed by Everts et al. Therefore, it is evident that CTX directly reflects the 
osteoclastic cathepsin K- dependent matrix degradation.
29
 
ESTIMATION OF CTX USING IMMUNOASSAYS 
                   Bonde M et al 
64 
in 1994 developed an Enzyme linked Immunosorbent 
Assay (ELISA) for quantifying type I collagen degradation products in urine. The 
peptide sequence used in this assay (Glu – Lys – Ala – His – Asp – Gly – Gly – Arg)  
was specific for the C – telopeptide α1 chain of type I collagen. The rationale behind 
using this sequence is: 
____________________________________________________________________Review of literature 
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 Important region for intermolecular crosslinks 
 Proximity of the crosslinking residues  
 Compact nature of these molecules protects these peptides from further renal 
degradation 
 Medium obtained from osteoclasts cultivated from bone slices showed the 
same amino acid sequence 
 C telopeptide fragments were reactive to ELISA 
             He concluded that collagen is the major constituent of bone, hence this 
peptide sequence is a potential marker for bone resorption. 
           Bonde M et al
63
 in 1997 developed an enzyme linked immunosorbent 
assay for measuring type I collagen degradation products in serum (S-ELISA) with 
an isomerised form of an eight amino acid sequence. He concluded that this assay is a 
sensitive and specific index of bone resorption and can be used to monitor patients 
with metabolic bone diseases. Fledelius C et al 1997
31
 studied the urinary fragments 
from C-terminal telopeptide of type I collagen. He reported that Asp-Gly site present 
in type I collagen is prone for isomerisation and the degree of isomerisation increases 
with increasing age of bone.  
             Direct competitive immunoassays for the quantification of CTX in urine 
requires only one CTX chain to react. A lysine residue (K) within the CTX epitope 
participates in inter- and intramolecular cross-links, joining two CTX epitopes.            
____________________________________________________________________Review of literature 
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                       Rosenqvist et al. 1998
80
 developed a new assay (Serum CrossLaps  One 
Step ELISA) for the determination of serum concentrations of the β-isomerized C-
telopeptide of type I collagen. This assay is performed as a monoclonal sandwich 
assay in a one-step procedure and is based on a monoclonal antibody that exclusively 
recognizes the isomerized β-aspartate (D) form of the EKAHβDGGR epitope of the 
α1-chain of human type I collagen.32 
                   The above kit was clinically tested by Christgau et al 1998
14 
for 
monitoring anti-resorptive treatment in osteoporosis treatment. He reported that the 
Serum one step ELISA was equivalent to the urine test that is commonly performed.  
                   Therefore it was confirmed that CTX can be determined in the serum by 
means of a sandwich assay employing two βCTX specific antibodies, and only 
molecules containing at least two β CTX chains (β-βCTX) are measured indicating 
mature (or “aged”) bone collagen. In contrast, α-αCTX can be measured by the 
recently developed ELISA, which is believed to reflect resorption of newly 
synthesized bone collagen.
16,17
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 ICTP as an index of MMP – DRIVEN COLLAGENOLYSIS: 
             Cross linked carboxyterminal telopeptide of type I collagen (ICTP) is 
generated by the action of MMPs. It requires a trivalent crosslink, including two 
phenylalanine-rich domains of the telopeptide region of the alpha – 1 chain of type I 
collagen.
77
 
            MMPs (MMP 2, 9, 13, 14) generate ICTP from insoluble collagen. ICTP is 
degraded by cathepsin K. MMPs from peri-osteoclastic cells compensate for inactive 
cathepsin K by degrading collagen that was demineralised by the osteoclast, and 
thereby generate ICTP.
37
 
CLINICAL SIGNIFICANCE OF CTX AND ICTP 
                          Lamster et al in 1994
39
 concluded in his study that the actual detection 
of connective tissue-derived molecules may lead to a more accurate assessment of 
tissue breakdown, because of the tremendous variability of the host response in 
different individuals.  The most immunogenic parts of the type I collagen are the 
telopeptides and there are several immunoassays for their specific measurement.
49,50
 
                         CTX is considered as the most specific and sensitive under normal 
remodeling conditions.
79,86
  Serum and urinary CTX levels have been reported to be 
efficient markers of bone resorption in many metabolic bone diseases, characterized 
by increased osteoclastic resorptive activity, including osteoporosis, Paget’s disease.37 
                      Serum ICTP is considered as a sensitive marker to detect osteolysis 
related to bone metastasis from breast, prostate cancers, or multiple myeloma. ICTP 
has been proven to be a poor marker in certain situations, especially osteoporosis, 
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where serum ICTP levels are not increased and do not respond to short – term 
antiresorptive therapy, including bisphosphonates.
37
 
                    Earlier GCF and salivary ICTP levels were considered to predict future 
alveolar bone loss in periodontitis
85
 and marker of advanced periodontitis
42
. Recently 
Gursoy et al reported that ICTP is a sensitive marker of neoplastic changes of bone 
and is less sensitive to osteoclasts – mediated degradation which occurs in 
periodontitis.
42
 
FACTORS RESPONSIBLE FOR VARIABILITY AND FLUCTUATIONS IN 
BONE MARKERS
62,67 
1. Diurnal rhythm - Bone marker levels are usually high in early morning hours 
and low in the afternoon and evenings. Most pronounced diurnal changes have 
been reported for CTX.  
2. Diet - Serum CTX values are affected by food intake. Therefore samples are 
collected  in fasting state           
3. Liver and renal diseases - CTX concentrations are affected in patients with 
liver and renal diseases. 
4. Puberty, Menopause and Pregnancy – Marker concentrations increase in 
puberty and menopause; decrease in pregnancy. 
5. Age: Marker levels are increased in men aged 20-40 yrs and decreased above 
50 yrs. 
6. Bed rest, exercise and seasonal changes also causes fluctuations in marker 
levels. 
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SALIVA – AS A DIAGNOSTIC MEDIUM 
                   The determination of markers of active disease (diagnostic tests) or 
prediction of disease (prognostic tests) using a non invasive diagnostic tool can 
provide accurate information of periodontal disease status.
60
 
                Saliva is a most valuable oral fluid which is used as a non – invasive 
diagnostic medium for various medical diagnosis and research procedures. The water 
content of saliva is approximately 99.5%. The pH of saliva is 5.6 – 7.6.  Saliva varies 
greatly in different individuals and in the same individual under different 
circumstances.
25 
                 Whole saliva consists of a mixture of oral fluids, and includes secretions of 
major and minor salivary glands, constituents of non – salivary origin (GCF),  
expectorated bronchial secretions, serum and blood cells from oral wounds, as well as 
bacteria and bacterial products, viruses and fungi, desquamated epithelial cells and 
food debris.
60
 
           Saliva has been evaluated as a diagnostic fluid for detecting caries risk
9
, 
periodontitis
15
, oral cancer
59
, breast cancer
84
, salivary gland diseases
46
, and systemic 
disorders such as hepatitis and the presence of human immune-deficiency virus
67
 or 
Hepatitis C virus.
27
 
             Salivary biomarkers can be categorized as proteomic markers (locally 
produced proteins of host and bacterial origin), genetic /genomic biomarkers such as 
DNA and mRNA of host origin, microbial markers (bacteria and bacterial products), 
steroid hormones and volatile compounds.
51
 Degradation products of type I collagen 
comes under proteomic markers.
60
 
____________________________________________________________________Review of literature 
16 
 
REVIEW OF STUDIES ON SERUM and URINARY CTX: 
                      Kushida K et al
55
 in 1995 compared marker of bone formation and 
resorption in post menopausal women and concluded that resorption markers (ALP, 
BGP, PYD, DPYD, CTX) increased in post menopausal women than formation 
markers. 
                     Garnero P et al
34
 in 1995 studied the different effects of bisphosphonate 
and estrogen therapy on free and peptide bound bone cross-links excretion and 
concluded that bisphosphonate therapy decreased markedly the cross‐linked peptides 
without significant change in free cross‐link excretion contrasting with a decrease of 
both free and peptide‐bound cross‐links after estrogen therapy. 
                       Bjarnson et al
6
 in 2000 conducted study to evaluate the early response 
in biochemical markers to predict long term response in bone mass during bone 
replacement therapy in early postmenopausal women. He reported that serum and 
urinary CTX after 2 weeks of therapy significantly correlated to 3 year bone mass 
response. 
                      Rosen et al 
79 
in 2000 in his study determined the utility of serum CTX 
and other markers in monitoring the efficacy of antiresorptive treatment. He 
concluded that serum CTX assay shows greater utility for assessing anti-resorptive 
treatment. 
                      Hosjing DJ et al
37
 in 2006 conducted study on biochemical assessment 
of Paget’s disease in bone. He reported that in untreated Paget's disease, the αCTX is 
raised proportionately more (16-fold) than βCTX (3-fold) and decreases in response to 
bisphosphonate therapy to a greater extent than βCTX (measured in the sCTX assay). 
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                       Marx R E et al
65
 in 2007 in his study reported that morning fasting 
serum CTX marker is a useful tool to assess the risk and time course of oral 
bisphosphonate induced osteonecrosis of the jaw. 
                       Garnero et al
38
 in 2008 in his study reported that measuring α/β ratio if 
type I collagen helps in predicting fracture risk in post menopausal women. 
                       Sonia Talwar et al
83 
in 2011 studied the bone turnover marker in 
osteoporosis. She reported that CTX responds remarkably to antiresorptive therapies. 
Serum ICTP is insensitive to normal metabolic bone processes, such as osteoporosis, 
but serum ICTP may be a marker of bone degradation in pathological conditions (eg, 
bone metastasis, rheumatoid arthritis).  
 
SALIVARY STUDIES ON CTX: 
                     Pelligrini et al
71
 in 2006 correlated between CTX and bone alkaline 
phosphatase in serum and saliva of rats. He concluded that salivary and serum CTX 
and b-AP correlated in both, normal conditions and in states of increased bone 
remodelling; the potential use of salivary markers for bone remodelling showed 
promising results. 
                   Pelligrini et al
72
 in 2008 conducted study on osteopenic rats to determine 
the correlation between serum and salivary markers on bone turnover. He concluded 
saliva may be one of the best candidate markers to determine the activity and severity 
of periodontal disease. 
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                 Pelligrini et al
73
 in 2012 determined the salivary bone turnover marker in 
healthy and pre- and post menopausal women on daily and circadian rhythm. His 
results concluded that as in serum and urinary samples, salivary CTX exhibits daily 
and a slight seasonal rhythmicity. Whole non-stimulated saliva is a useful and 
promising tool to test changes in bone metabolism contributing to diagnose and to 
monitor the therapy of several metabolic bone diseases. 
                Al  Sabbagh M et al in 2012
2
 examined the leves of salivary biomarkers 
associated with biological aspects of bone remodeling in subjects with chronic 
periodontitis. The markers analysed in the study are macrophage inflammatory protein 
1 – α (MIP - 1α), osteoprotegerin, C-terminal pyridinoline crosslinks of type I 
collagen (ICTP) and β – C terminal type I collagen telopeptide (βCTX). Amongst the 
markers anlysed, he concluded that MIP1 – α levels were significantly increased in 
chronic periodontitis subjects as compared to healthy controls. βCTX levels were at or 
below the detection limit (0.80µg/ml) in all samples. Hence βCTX was neither 
compared nor correlated with the clinical parameters. 
                Gursoy et al in 2012
42
 studied salivary degradation products of type I 
collagen and matrix metalloproteinases to detect potential markers of periodontitis 
with high sensitivity and specificity. He demonstrated that salivary CTX differed in 
patients with and without periodontitis. He concluded that MMP8 is a strong 
biomarker candidate for detecting alveolar bone destruction.    
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MATERIALS AND METHODS 
STUDY DESIGN AND SUBJECT SELECTION: 
            The study was approved by the Institutional Ethical Committee. A total of 45 
subjects were included in the study, from the out-patient ward of the Department of 
Periodontics, Tamil Nadu Government Dental College and Hospital, Chennai – 600 
003. Subjects were chosen based on the following inclusion and exclusion criteria. 
INCLUSION CRITERIA: 
1. Subjects willing for voluntary participation and signing the informed consent 
2. Systemically healthy subjects 
3. Age: 30 – 40 years 
4. Gender: Both males and females 
5. Patients with  generalized chronic periodontitis with minimum of 20 teeth 
EXCLUSION CRITERIA: 
1. History of any systemic illness 
2.  History of systemic antibiotics or anti-inflammatory drugs during past 6 
months 
3. Pregnancy, lactation and menopause62,69 
4. Patients who smoke or use tobacco in any form 
5. History of any periodontal treatment during the past 1year. 
The selected subjects were divided into 2 groups based on the following criteria: 
Group I – Control group (n=20) 
Group II – Study group (n=25) 
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CONTROL GROUP: 
      20 subjects exhibiting the following criteria
4,5
 were included: 
 Healthy controls with minimum of  20 teeth 
 < 20% sites with bleeding on probing 
 No sites with probing depth more than 3 mm 
 No evidence of radiographic bone loss 
 Good oral hygiene status (Plaque Index score less than 1) 
 
STUDY GROUP 
        25 subjects exhibiting the following criteria
4,5
 were included: 
 Chronic periodontitis with minimum of 20 teeth 
 Presence of bleeding on probing 
 >30% sites with Probing depth and Clinical Attachment Level (CAL) ≥5mm 
 Radiographic evidence of bone loss  
 Poor oral hygiene status ( plaque index score of 2.0 to 3.0) 
 
                      The present study is an interventional study. Saliva samples were 
collected at baseline in both the groups and after Phase I therapy in group II. Hence 
group II was further classified into: 
Group II A – before Phase I therapy 
Group II B – after Phase I therapy 
In addition, subjects should meet the following criteria: 
 Should have good oral hygiene throughout the periodontal treatment 
 Absence of any lesions in the oral cavity 
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STUDY PROTOCOL 
1. Medical History and Informed Consent 
2. Complete Periodontal Examination using clinical parameters namely  
Gingival Bleeding Index, Plaque Index, Probing Pocket Depth (PPD) and 
Clinical Attachment Level (CAL) 
3. Orthopantamogram (OPG) for radiographic evaluation of generalized 
chronic periodontitis (Group II) 
4. Bitewing radiographs (posterior) for Group II subjects. 
5. Collection of saliva samples. 
6. Oral hygiene instructions were given for group II subjects. 
7. Phase I therapy performed for Group II patients 
8. Re-evaluation of Group II patients using clinical parameters namely, 
Gingival Bleeding Index, Probing Pocket Depth and Clinical Attachment 
Level. 
9. Collection of saliva samples in Group II patients 1 month after Phase I 
therapy 
10. Estimation of CTX in saliva samples by ELISA method. 
CLINICAL PARAMETERS: 
GINGIVAL BLEEDING INDEX (Ainamo and Bay 1975)
1 
Teeth examined - All teeth except third molars 
Surfaces examined - 6 sites per tooth (Mesiobuccal, Midbuccal, 
Distobuccal, Mesiolingual,, Midlingual and 
Distolingual) 
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The presence or absence of bleeding is determined by gentle probing of the 
gingival crevice with a periodontal probe. 
CRITERIA FOR SCORING 
Positive score (+) - Presence of bleeding within 10 seconds  
Negative score (-) - Absence of bleeding 
         Total number of positive score 
     % of bleeding sites =             x 100 
    Total number of surfaces of all teeth 
 
PLAQUE INDEX (Silness and Loe 1964)
81 
 
Teeth examined – All teeth 
Surfaces examined – 4 sites per tooth (disto-facial, facial, mesio-facial, lingual 
/palatal).  
Criteria for Scoring: 
Score 0 – No plaque 
Score 1 – Film of plaque adhering to the tooth surface seen only by running a probe 
along the  tooth surface 
Score 2 – Moderate accumulation of soft deposits within the gingival pocket; can be 
seen by naked eye 
Score 3 – Abundance of soft matter within the gingival pocket / margin / adjacent 
tooth  
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 Calculation: 
Plaque index for the tooth = total score from 4 areas/4  
Plaque index for the individual = Total Plaque indices for all teeth / No. of 
teeth examined.                                
Interpretation:          Score 0 – Excellent oral hygiene 
                              0.1 to 0.9 – Good oral hygiene 
                  1.0 to 1.9 – Fair oral hygiene 
                  2.0 to 3.0 - Poor oral hygiene 
 
PROBING POCKET DEPTH (PPD in mm) (Grant 1965)
41
 (Carranza 10
th 
edn)
12 
 
Probing Pocket Depth was measured from the gingival margin to the base of 
the pocket using William’s Periodontal Probe.  The probe was walked within the 
gingival sulcus along the circumference of the tooth. Six measurements were made 
per tooth (Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, Midlingual, 
Distolingual). 
 
Calculation: 
                                                Sum of all scores per tooth 
PPD per tooth =              
                         6 
                                                   
                                                        Sum of each tooth score 
Mean PPD per person =              
    Total number of teeth examined 
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CLINICAL ATTACHMENT LEVEL (CAL in mm) (Carranza 10
th 
edn)
12  
 
 Clinical Attachment Level was measured from the Cemento – Enamel Junction 
(CEJ) to the base of the pocket in millimeters using William’s Periodontal 
Probe. Three measurements were made on the buccal aspect and three on the 
lingual aspect of each tooth – total of six sites per tooth (Mesiobuccal, 
Midbuccal, Distobuccal, Mesiolingual, Midlingual, and Distolingual). 
 
 If gingival margin is located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing pocket depth, the 
distance from the gingival margin to the CEJ.  If both were the same, the loss 
of attachment was calculated to be zero.  
 If the gingival margin coincides with the CEJ, the loss of attachment was 
calculated as equaling the probing pocket depth. 
 If the gingival margin is located apical to the CEJ, the loss of attachment was 
greater than the probing pocket depth and therefore the distance between the 
CEJ and the gingival margin were added to the PPD. 
Calculation: 
                                   Sum of all scores per tooth 
CAL per tooth =              
                  6 
 
                                    Sum of each tooth score 
 Mean CAL per person =            
              Total number of teeth examined 
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                           Subjects were selected randomly, with no discrimination in age and 
sex between both the groups.  Study protocol was explained and written informed 
consent (Annexure 2, 3) was obtained from all subjects. Thorough medical and dental 
history was obtained (Annexure 4). Each subject underwent periodontal examination 
and charting using the clinical parameters (gingival bleeding index, plaque index, 
probing pocket depth, clinical attachment level). Orthopantamogram was taken for 
Group II subjects. Radiographic bone loss was recorded dichotomously (presence or 
absence). Bitewing radiographs (posterior) were taken to confirm the bone loss. No 
delineation was done for Group II based on the extent of bone loss. 2ml of 
unstimulated whole saliva was collected at baseline from Group I and II. Oral hygiene 
instructions were given. Phase I therapy was performed for Group II subjects.  
                    Patients were re-evaluated after 1 month using same clinical parameters 
and 2ml of unstimulated whole saliva sample was collected from Group II B subjects 
after phase I therapy. Salivary CTX were estimated in the samples using Enzyme 
Linked Immunosorbent Assay. 
ARMAMENTARIUM 
CLINICAL EXAMINATION 
Mouth Mirror 
Williams Periodontal Probe 
Explorer 
Tweezer 
Cotton balls 
Kidney tray 
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Disposable Head Cap and Face mask 
Surgical Gloves 
COLLECTION OF SALIVA SAMPLE 
Vaccutainer tubes 
Sterile Cotton 
SAMPLE STORAGE 
-20°C Freezer 
FOR PHASE I THERAPY 
  
              Mouth Mirror  
              Explorer  
              Scalers and Curette  
                Kidney Tray with cotton Rolls  
               Disposable facemask and headcap  
               Surgical Gloves 
                Disposable syringe with 23 gauge needle  
                Local Anesthetic solution  
                Aspirating Needle  
                0.9% Normal Saline  
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ELISA PROCEDURE 
               Centrifuge Machine 
   Plastic rack 
   Autoclaved plastic pipette tips 
   Micropipette 
   ELISA washer and reader 
SALIVA SAMPLE COLLECTION 
               Unstimulated whole saliva samples were obtained from Group I (control 
group) at baseline and from Group II (study group) subjects before and after Phase I 
therapy. The subjects were advised to report in the morning following an overnight 
fast
61
. Samples were collected prior to clinical examination or any periodontal 
intervention. 2ml of saliva was collected in a vaccutainer immediately after single 
mouth rinse with water and stored in   -20°C freezer. 
ELISA PROCEDURE 
               Before testing, the collected samples were thawed to room temperature and 
centrifuged. The supernatant was used for the test. In this study, ELISA kit for Cross 
linked C-Telopeptide of Type I collagen (CTX 1), manufactured by USCN Life 
Science Inc., China was used. 
MATERIALS PROVIDED IN THE KIT 
Pre-coated, ready to use 96-well strip plate 
Standard (Lyophilised) 
Detection Reagent A (green) 
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Detection Reagent B (red) 
TMB Substrate 
Wash Buffer (30 x concentrate) 
Plate sealer for 96 wells 
Standard diluent 
Assay Diluent A (2 x concentrate) 
Assay Diluent B (2 x concentrate) 
Stop solution 
REAGENT PREPARATION 
1. All kit components were brought to room temperature (18-25°C) before use. 
2. Standard - The Standard was reconstituted with 0.5 mL of Standard Diluent, kept 
for 10 minutes at room temperature. The concentration of the standard in the stock 
solution is 10000pg/mL. 
 3. 5 tubes containing 0.6mL Standard Diluent were prepared and a triple dilution 
series was done.  
 
                                 Figure 3: Triple dilution series for Standard diluents 
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4. Each tube was mixed thoroughly before the next transfer.  5 points of diluted 
standard such as 10,000pg/ml, 3,333pg/ml, 1,111pg/ml, 370.4pg/ml, 123.5pg/ml was 
set and the last EP tubes with Standard Diluent was considered blank as 0pg/mL. 
5. Assay Diluent A and Assay Diluent B - 6mL of Assay Diluent A or B 
Concentrate(2×) was diluted with 6mL of deionized or distilled water to prepare 12 
mL of Assay Diluent A or B.  
6. Detection Reagent A and Detection Reagent B -The working concentration was 
diluted with working Assay Diluent A or B, respectively (1:100). 
7. Wash Solution - 20mL of Wash Solution concentrate (30×) was diluted with 580mL 
of deionized or distilled water to prepare 600 mL of Wash Solution (1×). 
8. TMB substrate - The needed dosage of the solution was aspirated with sterilized 
tips. 
ASSAY PROCEDURE 
1. The wells for diluted standard, blank and sample were determined- 5 wells for 
standard, 1 well for blank. 
2. 50μL each of dilutions of standard, blank and samples were added into the 
appropriate wells. 
3. 50μL of Detection Reagent A working solution was added to each well. The 
plate was sealed with plate sealer and incubated at 37°C. 
4. The solution was aspirated and washed with 350μL of 1× Wash Solution using 
an autowasher. The remaining liquid from all wells was removed completely 
by snapping the plate onto absorbent paper. The process was repeated 3 times.  
5. 100μL of Detection Reagent B working solution was added to each well. The 
plate was covered with plate sealer and incubated for 30 minutes at 37°C 
6. The aspiration/wash process was repeated for five times. 
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7. 90μL of Substrate Solution was added to each well. Covered with plate sealer 
and incubated for 15 - 25 minutes at 37°C.  The liquid turned blue after the 
addition of Substrate Solution. 
8. 50μL of Stop Solution was added to each well. The liquid turned yellow by the 
addition of Stop solution.  
9. The plate was placed on the microplate reader and measured at 450nm 
immediately. 
 
CALCULATION OF RESULTS 
               This assay employs the competitive inhibition enzyme immunoassay 
technique, so there is an inverse correlation between CTX I concentration in the 
sample and the assay signal intensity. Average was calculated for the duplicate 
readings for each standard, control and samples. In order to make the calculation 
easier, standard curve was drawn with optical density value on the Y-axis and 
concentration of the standard on the X-axis. 
 
                          
Figure 4:  Standard Curve for CTX 
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Photograph 1: Control group 
 
                                   
 
Photograph 2: Generalised Chronic Periodontitis (study group) 
 
 
 
Photograph 3: Orthopantamogram of study group 
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         Photograph 4: Posterior horizontal bitewing radiograph of study group 
 
 
Photograph 5: Armamentarium for periodontal examination 
 
 
Photograph 6: Collected saliva samples in vaccutainer 
34 
 
 
Photograph 7: Armamentarium for Phase I therapy 
 
 
Photograph 8: Probing depth measured using Williams periodontal probe before 
phase I therapy 
 
 
Photograph 9: Probing depth measured using Williams periodontal probe after 
phase I therapy 
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Photograph 10: Centrifuge Machine 
 
 
 
 
              Photograph 11: Deep Freezer and samples stored at -20°C 
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Photograph 12 : ELISA kit contents 
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                                           Photograph 13: 96 microplate of ELISA kit 
 
 
Photograph 14: Micropipettes 
 
 
  
                       Photograph 15: ELISA reader and washer 
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Photograph 16: 96 well microplate after adding substrate solution 
                              
 
Photograph 17: 96 well microplate on autowasher 
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Photograph 18: 96 well microplate with conjugate solution 
 
 
 
Photograph 19: 96 well microplate on ELISA reader 
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STATISTICAL ANALYSIS 
            The statistical analysis was done using the computer software program SPSS 
(Statistical Package for Social Sciences) version 17. 
Mean and Standard Deviation were estimated for different variables in each 
group. Mean values were compared between the two groups by using Student’s 
Independent t-test. 
            Paired t test was used to compare the mean values within the same group. 
          Chi-square test was done to compare the gender distribution between the two 
groups 
          Pearson’s correlation co-efficient was used to analyse the correlation between 
the clinical parameter and salivary CTX level.  
          In the present study, P-value <0.05 was considered as the level of significance.       
 
STATISTICAL FORMULAE USED FOR DATA ANALYSIS 
Student’s independent t-test 
The independent t-test was used to compare the statistical significance of a 
possible difference between the means of two groups on some independent variable 
and the two groups were independent of one another. 
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The formula for the independent t-test was 
,  
Where, 
is the mean for group 1, 
is the mean for group 2, 
is the sum of squares for group 1, 
is the sum of squares for group 2, 
n1 is the number of subjects in group 1, and 
n2 is the number of subjects in group 2. 
                 
The t-value found was the difference between the two means divided by their sum of 
squares and taking the degrees of freedom into consideration. 
 and        
The degree of freedom for the independent t-test used was: 
  
Paired t - test: 
                      A paired t-test is used to compare two population means where you have 
two samples in which observations in one sample can be paired with observations in 
the other sample. 
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The top of the formula is the sum of the differences (i.e. the sum of d). The bottom of 
the formula reads as:  
The square root of the following: n times the sum of the squared differences minus the 
sum of the differences squared, all over n-1.  
 The sum of the squared differences: ∑d2 means take each difference in turn, 
square it, and add up all those squared numbers.  
 The sum of the differences squared: (∑d)2 means add up all the differences and 
square the result. 
PEARSON’S CHI-SQUARE TEST 
Chi-square is a statistical test commonly used to compare observed data with data we 
would expect to obtain according to a specific hypothesis. 
The formula used was  
 
P – VALUE  
              The p-value measures consistency between the results actually obtained in 
the trial and the pure chance explanation for those results. In statistical hypothesis 
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testing, the p-value is the probability of obtaining a test statistic at least as extreme as 
the one that was actually observed, assuming that the null hypothesis is true.  
0.05 < P < 0.10      Weak evidence against the null hypothesis in favor of the    
                               alternative 
0.01 < P < 0.05      Moderate evidence against the null hypothesis in favor of the 
                               alternative. 
P < 0.01                 Strong evidence against the null hypothesis in favor of the 
                              alternative. 
P < 0.001               Very strong evidence against the null hypothesis in favor of the 
                               alternative 
In this study differences between the two populations were considered significant 
when p < 0.05. 
 
PEARSON’S CORRELATION CO-EFFICIENT 
Pearson’s correlation coefficient is the method of measuring the correlation.  
Degree of correlation: 
1. Perfect: If the value is near ± 1, then it is said to be a perfect correlation. 
2. High degree: If the value lies between ± 0.75 and ± 1, then it is said to be a 
high degree of correlation. 
3. Moderate degree: If the value lies between ± 0.25 and ± 0.75, then it is said 
to be moderate degree of correlation. 
4. Low degree: When the value lies between 0 and ± 0.25, then it is said to be a 
low degree of correlation. 
5. No correlation: When the value is zero 
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RESULTS 
            The present study is an interventional study with a total of 45 subjects. The 
subjects were divided into 2 groups: 
             Group I – control group (n=20) 
              Group II – study group (n=25) 
            Samples were collected from Group I and II at baseline and from Group II 
after phase I therapy. Hence Group II was further categorized into 
              Group II A – before phase I therapy 
              Group II B – after phase I therapy 
  The statistical analysis was performed and results were tabulated. 
 
Table 1 and 2  shows the master chart of the Group I and Group II with 
the clinical  parameters and salivary CTX level .  
.  
Table 3 and Figure 5 shows the comparison of age between Group I and Group II.  
The mean age in the Group I was 36.05 years and 35.08 years in the Group II 
respectively. There was no statistical ly significant difference in the 
distribution of age in both the groups.  
 
Table 4 and Figure 6 shows the comparison of gender distribution between the study 
and control group. The males constituted 45.8% in Group I and 54.2% in Group II. 
Females constituted about 42.9% in Group I and 57.1% Group II.  There was no 
statistical ly significant difference in distribution of the gender  between 
the groups.  
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Plaque Index (PI) 
                 The mean Plaque Index score in Group I was 0.26 ± 0.22 and 2.58 ± 0.15 in 
Group II which was statistically highly significant (p<0.01**).  Positive correlation 
was observed between Plaque Index and salivary CTX level in Group I and Group II 
but the correlation was not significant.(p>0.05) (Table 5, 11, 12 and Figure 7, 14, 17) 
 
Gingival Bleeding Index (GBI) 
                   The gingival bleeding index was significantly increased in the Group IIA 
(96.22±2.54) as compared to the control group (15.57 ± 6.06) (Table 5 and Figure 8) 
with p value < 0.01**, which reduced to 21.79 ± 7.25 following phase I periodontal 
therapy with a p <0.01** (Table 7 and Figure 8). The gingival bleeding index 
showed positive correlation with salivary CTX in group I, IIA and IIB but the 
correlation was not significant. (p>0.05) (Table 11, 12, 13 and Figure 15, 18, 21) 
 
Probing Pocket Depth (PPD) 
               The PPD was significantly increased in the study group (6.27 ± 0.93mm) as 
compared to control group (2.84 ± 0.53mm) with p value <0.01** (Table 5 and 
Figure 9). The probing depth reduced considerably following treatment to 3.07 ± 0.68 
mm (p value <0.01**) (Table 7 and Figure 9), but not to the level of the control 
group (p value <0.01**) (Table9 and Figure 9). Linear correlation was observed 
between probing depth and salivary CTX levels in all the groups but the correlation 
was not significant.(Table 11, 12, 13 and Figure 16, 19, 22) 
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Clinical Attachment Level (CAL) 
                    In the study group, a statistically significant difference was found 
between group II-A (6.93 ± 0.64mm) and group II-B (4.22 ± 0.52mm) values with p 
value <0.01** (Table 7 and Figure 10). Since the loss in the clinical attachment level 
in control group was absent the comparisons with that group was highly significant. 
Positive correlation was observed between CAL and salivary CTX but the correlation 
was not significant.(Table 11, 12, 13 and figure 20, 23) 
 
Salivary CTX level 
                   The mean salivary CTX levels were 152.98±16.74 pg/ml in the study 
group and 38.78±6.22 pg/ml in the control group. There was high statistical 
significant difference in salivary CTX levels between the study and the control group. 
(Table 6 and Figure 1) 
                   Highly significant difference (p<0.01**) was observed on comparing the 
salivary CTX level between Group II subjects before (152.98 ±6.22 pg/ml) and after 
(80.90±19.90 pg/ml) therapy. (Table 8 and Figure 12) 
                   Comparison of salivary CTX level between Group I (control group) and 
Group II (study group) after phase I therapy was also highly significant (p<0.01**). It 
implies that the levels did not reduce to the level of the controls after phase I therapy. 
(Table 10 and Figure 13) 
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TABLE 1 – MASTER CHART – GROUP I (CONTROL GROUP) 
S.No 
AGE 
(yrs) SEX PI GBI (%) 
PPD 
(mm) 
CAL 
(mm) 
CTX 
(pg/ml) 
C1 31 M 0.27 21.5 2.9 0 30.1 
C2 33 M 0.14 10.34 2.3 0 41.7 
C3 32 F 0.36 14 2.14 0 39.4 
C4 35 M 0.52 17.5 3.02 0 41.2 
C5 37 F 0.87 8.12 2.68 0 38.4 
C6 32 F 0.11 20.17 2.44 0 33.9 
C7 36 M 0.09 6.98 2.33 0 42.2 
C8 35 F 0.02 13.72 2.11 0 41.4 
C9 31 F 0.33 21.67 2.24 0 29.5 
C10 30 M 0.24 11 3.12 0 31.1 
C11 31 F 0.07 24.33 3.77 0 37.6 
C12 34 F 0.04 17.34 3.03 0 45.9 
C13 37 M 0.23 7.02 2.87 0 44.3 
C14 38 M 0.17 13.72 3.11 0 47.8 
C15 31 M 0.31 5.2 3.86 0 32.5 
C16 31 F 0.42 16.79 3.13 0 34.8 
C17 32 F 0.67 24.22 2.17 0 36.1 
C18 32 M 0.25 21.33 2.91 0 40.6 
C19 37 F 0.06 14.21 3.57 0 48.3 
C20 39 F 0.15 22.15 3.24 0 28.1 
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TABLE 2 – MASTER CHART – GROUP II (STUDY GROUP) 
S.No 
AGE  
(yrs) SEX PI 
GBI-1 
(%) 
PPD-1 
(mm) 
CAL-1 
(mm) 
CTX-1 
(pg/ml) 
GBI-2 
(%) 
PPD-2 
(mm) 
CAL-2 
(mm) 
CTX-2 
(pp/ml) 
S1 37 M 2.63 100 5.79 6.12 172.8 12.1 2.59 3.31 94.3 
S2 37 F 2.89 94.72 6.11 6.74 137.5 15.1 4.1 4.56 56.5 
S3 43 M 2.5 100 7.67 7.17 143.2 28.05 4.67 5.12 96.3 
S4 32 M 2.57 95.13 6.96 7.54 119.8 31.22 3.12 4.31 44.6 
S5 36 F 2.54 100 5.98 6.32 147.1 18 3.07 4.23 92.2 
S6 33 F 2.6 96.23 6.23 6.94 151.3 10.74 2.47 4.12 101.3 
S7 32 M 2.37 89.98 6.4 7.14 142.2 34.3 3.51 4.77 80.4 
S8 33 M 2.46 94.12 5.37 6.77 167.1 19.27 2.23 3.78 95.6 
S9 37 M 2.74 97.36 5.1 6.24 165.4 23.44 2.27 3.68 98.2 
S10 36 F 2.41 96.11 7.94 8.1 130.7 27.12 3.54 4.18 80.8 
S11 39 F 2.68 97.13 5.56 6.32 167.2 35.14 3.29 3.66 105.6 
S12 40 F 2.51 95.04 6.29 6.85 154.3 11.91 3.35 5.07 90.6 
S13 39 F 2.77 93.9 4.34 5.97 161.9 24.12 2.12 4.11 96.3 
S14 40 M 2.34 100 5.92 6.33 139.9 26.43 2.35 4.32 83.3 
S15 41 M 2.43 95.84 5.65 6.92 155.2 29 2.97 3.78 58.3 
S16 33 M 2.39 98.11 6.77 6.84 175.5 23.43 3.24 4.23 51.7 
S17 42 F 2.67 94.34 7.81 8.23 172.7 20.97 2.54 3.64 49.2 
S18 42 F 2.53 91.86 5.75 6.51 151.9 15.24 3.14 3.91 100.5 
S19 38 M 2.44 97.14 6.91 7.29 125.9 17.89 4.27 5.34 95.9 
S20 40 M 2.56 93.54 7.88 8.15 127.4 27.34 3.1 4.71 71.1 
S21 42 M 2.72 97.36 7.21 7.97 166.1 28.12 2.77 3.62 54.9 
S22 34 F 2.58 96.02 5.12 6.54 155.8 23.14 3.63 4.73 94.3 
S23 36 M 2.9 98.12 6.05 6.98 145.6 12 2.35 3.78 56.5 
S24 34 F 2.58 95.48 5.92 6.41 178.2 14.91 2.42 4.11 104 
S25 37 F 2.72 97.9 6.16 6.97 169.8 15.83 3.78 4.57 70.3 
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TABLE 3 – COMPARISON OF AGE BETWEEN GROUP I AND GROUP II 
 
AGE (in years) 
Group I Group II P value 
Mean S.D Mean S.D 
36.05 2.038 35.08 3.000 0.752$ 
$ – not significant 
 
 
 
         TABLE 4 – COMPARISON OF GENDER BETWEEN GROUP I AND II 
 Group Total P value 
I II   
 
 
 
 
 
0.841$ 
Sex Male Count 11 13 24 
 % within 
sex 
45.8 54.2 100 
% within 
group 
55 52 53.3 
Female Count 9 12 21 
 % within 
sex 
42.9 57.1 100 
% within 
group 
45 48 46.7 
Total Count 20 25 45 
 % within 
sex 
44.4 55.6 100 
% within 
group 
100 100 100 
$ – not significant 
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TABLE 5 - COMPARISON OF CLINICAL PARAMETERS BETWEEN 
GROUP I AND GROUP II A 
 Group Mean S.D P value 
PI I 0.26 0.22  
0.000
** 
II A 2.58 0.15 
GBI (%) I 15.57 6.06  
0.000
** 
II A 96.22 2.54 
PPD (mm) I 2.84 0.53  
0.000
** 
II A 6.27 0.93 
CAL (mm) I 0.00 0.00  
0.000
** 
II A 6.93 0.64 
** < 0.01 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
 
 
TABLE 6 - COMPARISON OF SALIVARY CTX BETWEENGROUP I AND         
GROUP II A 
 Group I  Group IIA  P value 
 
CTX 
(pg/ml) 
Mean S.D Mean S.D  
0.000
** 
38.39 6.22 152.98 16.74 
** < 0.01 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
 
 
 
51 
 
TABLE 7 – COMPARISON OF CLINICAL PARAMETERS BETWEEN 
GROUP II A AND GROUP II B 
 Group Mean S.D P value 
GBI (%) II A 96.22 2.54  
0.000
** 
II B 21.79 7.25 
PPD (mm) II A 6.27 0.93  
0.000
** 
II B 3.07 0.68 
CAL (mm) II A 6.93 0.64  
0.000
** 
II B 4.22 0.52 
** < 0.001 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
 
 
 
TABLE 8 – COMPARISON OF SALIVARY CTX BETWEEN GROUP II A 
AND GROUP II B 
 Group II A Group II B P value 
CTX (pg/ml)  Mean S.D Mean S.D  
0.000
**
 152.98 6.22 80.90 19.90 
** < 0.001 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
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TABLE 9 – COMPARISON OF CLINICAL PARAMETERS BETWEEN 
GROUP I AND GROUP II B 
 Group Mean S.D P value 
GBI (%) I 15.57 6.06 0.000
** 
II B 21.79 7.25 
PPD (mm) I 2.84 0.53 0.000
** 
II B 3.07 0.68 
CAL (mm) I 0.00 0.00 0.000
** 
II B 4.22 0.52 
** < 0.001 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
 
 
 
 
TABLE 10 – COMPARISON OF SALIVARY CTX BETWEEN GROUP I AND     
GROUP II B 
 Group I Group II B P value 
CTX (pg/ml)  Mean S.D Mean S.D  
0.000
**
 38.39 6.22 80.90 19.90 
** < 0.001 – highly significant *0.05-0.01 – significant $ >0.05 – not significant 
 
 
 
53 
 
TABLE 11 - CORRELATION BETWEEN CLINICAL PARAMETERS AND   
SALIVARY CTX LEVEL IN GROUP I 
 
CLINICAL PARAMETER CTX 
PI Pearson Correlation 0.254
 
Sig. (2-tailed) 0.279$
 
GBI Pearson Correlation 0.198 
Sig. (2-tailed) 0.402$
 
PPD Pearson Correlation 0.32 
Sig. (2-tailed) 0.168$
 
CAL Pearson Correlation 0.274 
Sig. (2-tailed) 0.242$
 
* significant (p<0.05) $ - not significant 
 
 
TABLE 12 – CORRELATION BETWEEN CLINICAL PARAMETERS AND 
SALIVARY CTX LEVEL IN GROUP II A (study group before Phase I therapy) 
 
CLINICAL PARAMETER CTX-1 
PI Pearson Correlation 0.236
 
Sig. (2-tailed) 0.256$
 
GBI -1 Pearson Correlation 0.365 
Sig. (2-tailed) 0.072$
 
PPD-1 Pearson Correlation 0.347 
Sig. (2-tailed) 0.089$
 
CAL-1 Pearson Correlation 0.156 
Sig. (2-tailed) 0.456$
 
                * significant (p<0.05)  $ - not significant 
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TABLE 13 – CORRELATION BETWEEN CLINICAL PARAMETERS AND 
SALIVARY CTX LEVEL IN GROUP II B (study group after Phase I therapy) 
 
CLINICAL PARAMETER CTX-1 
GBI -2 Pearson Correlation 0.361
 
Sig. (2-tailed) 0.076$
 
PPD-2 Pearson Correlation 0.293 
Sig. (2-tailed) 0.155$
 
CAL-2 Pearson Correlation 0.214 
Sig. (2-tailed) 0.304$
 
                * significant (p<0.05)  $ - not significant 
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Figure 5:  Comparison of age between control (group I) and study 
(group II) group 
 
 
 
 
Figure 6: Comparison of gender between group I and group II 
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Figure 7: Comparison of mean plaque index between group I 
(control) and group IIA (study group before phase I therapy) 
 
 
 
 
Figure 8: Comparison of Gingival Bleeding Index between group I, 
group IIA and group IIB (study group after phase I therapy) 
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Figure 9: Comparison of probing pocket depth between group I , 
group IIA and group IIB 
 
 
 
 
Figure 10: Comparison of clinical attachment level between group I, 
group IIA and group IIB 
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Figure 11: Comparison of Mean salivary CTX between group I and 
group IIA 
 
 
 
 
Figure 12: Comparison of Mean salivary CTX between group IIA 
and group IIB 
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Figure 13: Comparison of Mean salivary CTX between group I and 
group IIB 
 
 
 
 
Figure 14: Correlation of Plaque Index and salivary CTX level in 
control group 
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Figure 15: Correlation of Gingival bleeding index (GBI) and salivary 
CTX level in control group 
 
 
 
 
Figure 16: Correlation of Probing Pocket Depth(PPD) and salivary 
CTX level in control group 
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Figure 17: Correlation of Plaque Index and salivary CTX level in 
study group (group IIA) 
 
 
 
 
Figure 18: Correlation of Gingival bleeding index and salivary CTX 
level in study group (group IIA) 
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Figure 19: Correlation of Probing pocket depth and salivary CTX 
level in study group (group IIA) 
 
 
 
 
Figure 20: Correlation of Clinical Attachment Level (CAL) and 
salivary CTX level in study group (group IIA) 
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Figure 21: Correlation of Gingival Bleeding Index (GBI) and salivary 
CTX level in study group IIB 
 
 
 
 
Figure 22: Correlation of Probing Pocket Depth (PPD) and salivary 
CTX level in study group IIB 
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Figure 23: Correlation of Clinical Attachment Level (CAL) and 
salivary CTX level in study group IIB 
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DISCUSSION 
                   Diagnostic testing has been a great challenge in periodontology, as the 
disease has a multifactorial etiology and its progression is characterized by periods of 
quiescence interspersed with episodes of acute destruction.
82
 Most importantly the 
diagnostic measures (probing depth, bleeding on probing, radiographic assessment) 
used for assessing periodontal disease status provide information about the past 
disease and fail to diagnose the current disease status.
86
 Moreover they are not reliable 
for identifying individuals with progressing disease activity.
26
 
                   Biomarkers of disease activity facilitate earlier detection of disease and 
helps in monitoring therapy outcomes.
86
Recently, salivary markers have been 
investigated for assessment of periodontal disease activity and its response to 
treatment.  
              Markers of collagen degradation such as pyridinoline, deoxypyridinoline, 
ICTP and CTX are being used to analyse the normal and pathologic processes in 
bone.
33
 
                  In the literature, pyridinoline cross linked carboxyterminal telopeptide of 
type I collagen (ICTP) is reported to be more specific for bone resorption and is  
considered as a good tool for assessing metabolic bone diseases like osteoporosis, 
rheumatoid arthritis and bone metastases.
86,39
 
                 Amongst the diagnostic biomarkers for periodontal diseases, Giannobile et 
al reported that ICTP is a good predictor of future alveolar bone and attachment loss. 
Also ICTP levels correlated with clinical parameters, periodontal pathogens and 
demonstrates significant reductions after periodontal therapy.
39, 42
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                   But Garnero et al reported that type I collagen breakdown products ICTP 
and CTX, reveal two distinct enzymatic pathways and are detected in different 
pathological conditions. The cathepsin K related pathway releases large amounts of 
CTX but destroys the ICTP epitope. The other, MMP related pathway generates ICTP 
fragments.
37
    
                 CTX is reported as an efficient marker of bone resorption in metabolic 
bone diseases characterized by increased osteoclastic activity like osteoporosis, Pagets 
disease etc. On the other hand, ICTP is a sensitive marker to detect osteolysis related 
to bone metastasis.
37, 42 
                There are only few studies about CTX in relation to periodontal diseases. 
Miller et al analysed the salivary biomarkers of periodontal disease and hypothesized 
that during active resorption of bone, CTX is released into the periodontal tissues, 
collected in GCF and is transferred to whole saliva. Hence saliva can be used to assess 
the disease activity and to monitor periodontal therapy.
18
 
                   Pellegrini G et al conducted a study in rats to correlate the serum and 
salivary markers of bone turnover and concluded that salivary CTX may be one of the 
best candidates to detect the activity and severity of periodontal disease.
71
 
                   Recently Gursoy et al reported that salivary CTX levels differed in 
subjects with and without chronic periodontitis.
43
 
                  Hence, the present study was conducted in subjects with generalized 
chronic periodontitis (n=25) and healthy subjects (n=20) to detect and compare 
salivary CTX levels before and after Phase I therapy. To our knowledge this is the 
first study in which salivary CTX has been evaluated in chronic periodontitis patients 
before and after periodontal therapy. 
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                    Thorough medical history was obtained from the subjects before including 
in the study, as variations in the marker level have been reported in liver diseases, 
renal diseases, diseases related to bone, etc.
62, 69
 
                   Bone markers exhibit substantial short-term and long-term fluctuations 
related to age of the individual, health status, time of day, phase of the menstrual 
cycle, season of the year, diet and exercise. These biological factors produce intra and 
inter-individual variations in markers.
62, 69
 
                    After 40 yrs of age, for every remodeling cycle there is a net loss of bone 
because the amount of bone resorption is more when compared to bone formation.
62,69
 
Hence in this study subjects of age group 30 – 40 yrs were recruited. The mean age 
calculated was 36.05 and 35.08 in the control and study group which was well within 
the inclusion criteria. 
                    Bone marker concentrations exhibit considerable variations during 
puberty, menstruation, pregnancy and menopause due to the effect of various 
hormone levels. Hence female subjects in their menstruation, pregnancy and 
menopause period were excluded from the study.
62, 69
 
                   Although GCF is site specific, whole saliva represents a pooled sample of 
all periodontally involved sites and is potentially useful in detecting individuals at 
risk. Stimulated whole saliva is less suitable for diagnostic applications because the 
foreign substances used to stimulate saliva tend to modulate the fluid pH and 
stimulate the water phase of saliva secretion, resulting in dilution in the concentration 
of proteins of interest
18
. In the present study, unstimulated whole saliva was collected 
from both the groups at baseline and in Group II after phase I therapy. 
                   Owing to diurnal and dietary influences on CTX levels, saliva samples 
were collected from the study subjects in the morning hours following an overnight 
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fast. CTX marker in serum and salivary samples are reported to be stable at -20
0
C
61
. 
Therefore the collected samples were stored at -20
0
C. 
                In the present study, CTX was detected in all saliva samples from patients 
with chronic periodontitis and healthy controls (detection limit of the kit used in the 
present study – 44.7pg/ml). On the contrary, in the study by Al Sabbagh et al2, 
salivary CTX levels were below the detection limit (0.80µg/ml) in all the samples.   
                 In another study by Gursoy et al CTX was detected only in 63% and 58% 
of subjects with and without generalized chronic periodontitis respectively.
43
  
Moreover, the minimum detection limit of the kit used by Gursoy et al
43
 is 0.02ng/ml 
while the kit used in the present study had a higher minimum detection limit          
(44.7 pg/ml).   
                In the present study, salivary CTX was increased in the study group (mean – 
38.39 pg/ml) when compared to the control group (mean – 152.98 pg/ml) with highly 
significant difference (p<0.01). This signifies that cathepsin K enzyme has taken part 
in the degradation of type I collagen and carboxyterminal telopeptide of type I 
collagen (CTX) has been released into periodontal tissues which has reached the 
saliva via GCF and has been detected by ELISA.   
                The clinical parameters namely the plaque index and gingival bleeding 
index, probing depth, clinical attachment level were correlated with salivary CTX 
levels in the control and study group.  Positive correlation was observed between the 
clinical parameters and salivary CTX level in all the groups but the correlation was 
not significant. This might be probably due to the low sample size (n=45) in this 
study. 
                On comparing the mean values of the clinical parameters, a highly 
significant difference was shown before and after phase I therapy in study group. Also 
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positive correlation was observed between the clinical parameters and salivary CTX 
levels after phase I therapy. This signifies that the inflammation was reduced after 
therapy and gain in the clinical attachment level was obtained.  
                On evaluation of salivary CTX levels in study group before and after phase 
I therapy highly significant difference (p<0.01) was observed.  However, the salivary 
CTX levels after phase I therapy were not reduced to the level of controls. This 
signifies the role of host response to periodontal treatment which varies from patient 
to patient. Also the observation period after phase I therapy could have been 
prolonged, which could have resulted in further reduction of salivary CTX levels.                                                                                                                                                                             
Moreover, evaluation of CTX levels after surgical phase of periodontal therapy could 
have resulted in levels closer to control group. Hence further studies can be conducted 
to evaluate salivary CTX levels after the surgical phase of periodontal therapy.    
                In the present study significantly elevated salivary CTX levels were 
observed in patients with chronic periodontitis as compared to healthy controls and 
their levels reduced in study group after therapy. This suggests a close association 
between salivary CTX and periodontal disease. Thus, salivary CTX might be 
potentially useful in distinguishing health from disease and monitoring periodontal 
disease activity.  
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SUMMARY AND CONCLUSION 
                    In this study, bone resorption marker, carboxyterminal telopeptide of type 
I collagen (CTX) levels in unstimulated whole saliva of periodontally healthy subjects 
(n=20) and generalized chronic periodontitis subjects (n=25) were analysed at 
baseline using Enzyme linked Immuosorbent assay (ELISA). Group IIA underwent 
Phase I therapy and were analysed for salivary CTX after therapy using the same 
technique. 
 The collected data was analysed and showed that, 
 CTX was detected in saliva of chronic periodontitis and healthy control 
subjects 
 Salivary CTX level was significantly increased in chronic periodontitis 
subjects as compared to healthy controls. 
 Positive correlation was shown between the clinical parameters and salivary 
CTX levels in both the groups but the correlation was not significant. 
 Significant reduction in salivary CTX levels was seen after phase I therapy in 
chronic periodontitis group but did not reduce to the level of healthy controls. 
            The limitations of the study was the small sample size (n=45) and short time 
period between observations in the study group. Within the limits of the study, it can 
be concluded that salivary CTX might be potentially useful in distinguishing health 
from disease and monitoring periodontal disease activity. Future longitudinal studies 
with larger sample size are needed to validate salivary CTX as a marker for 
periodontal disease.  
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Annexure - 1 
INFORMATION SHEET 
 
 We are conducting a study on effect of phase I therapy on Salivary 
Carboxyterminal telopeptide  levels in chronic periodontitis patients. 
 The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
 Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
 
 
 
Name of the patient               Signature / Thumb impression  
 
 
 
 
Name of the investigator              Signature   Date 
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Annexure – 2 
 
INFORMED CONSENT FORM 
 
STUDY TITLE: 
 
EFFECT OF PHASE I THERAPY ON SALIVARY 
CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN IN                                    
CHRONIC PERIODONTITIS PATIENTS 
 
 
Name:        O.P.No: 
 
Address:                  Code No: 
 
                   Age / Sex:  
        
                   Tel. no: 
 
I, ___________________________________________________age____years 
exercising my free power of choice, hereby give my consent to be included as 
a participant in the study “Effect of phase I therapy on salivary  
carboxyterminal telopeptide of type I collagen in chronic periodontitis 
patients ” 
I agree to the following: 
  
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my body 
function. 
 I agree to co-operate fully and to inform my doctor immediately if I suffer any 
unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking. 
 I hereby give permission to use my medical records for research purpose. I am 
told that the investigating doctor and institution will keep my identity 
confidential. 
 
 
Name of the patient   Signature / Thumb impression  
 
 
 
Name of the investigator   Signature       
Date 
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Annexure - 3 
  
TAMIL CONSENT FORM 
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Annexure 4 
 
EFFECT OF PHASE I THERAPY ON  SALIVARY 
CARBOXYTERMINAL TELOPEPTIDE LEVELS IN 
CHRONIC PERIODONTITIS PATIENTS 
 
PROFORMA 
Name  :      Age / Gender: 
 
O.P. No :       Code No: 
 
Occupation :      Income    : 
 
Address and Contact No.:              
 
 
Chief Complaints 
 
Duration: 
Medical history 
Dental history 
Periodontal Examination                
                                              PLAQUE INDEX – SILNESS & LOE (1964) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score:  
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GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score: 
 
PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) (in mm) 
MAXILLARY:    
     Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
MANDIBULAR: 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Buccal 
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DIAGNOSIS: 
INVESTIGATIONS: 
OPG 
 
BITEWING RADIOGRAPHS 
 
SALIVARY CTX LEVEL 
TREATMENT  
 
 
 
 
 
AFTER PHASE I THERAPY (after 1 month) 
 
GINGIVAL BLEEDING INDEX – AINAMO & BAY (1975) 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score:  
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PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) (in mm) 
MAXILLARY:    
     Palatal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Buccal 
MANDIBULAR: 
     Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Buccal 
INVESTIGATION: 
SALIVARY CTX LEVEL: 
INFERENCE: 
 
 
 
Signature of the P.G student      Signature of Guide 
Date    
